Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach

Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy f...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1255021
Main Authors Franchini, Fanny, Fedyashov, Victor, IJzerman, Maarten J., Degeling, Koen
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 30.10.2023
Subjects
Online AccessGet full text
ISSN1663-9812
1663-9812
DOI10.3389/fphar.2023.1255021

Cover

Abstract Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data. Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R. Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study. Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
AbstractList Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data.Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R.Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study.Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data. Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R. Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study. Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data. Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R. Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study. Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific probabilities and distributions (ESPD) approach when dealing with censored data remains. This study defines and illustrates the ESPD strategy for censored data. Methods: The ESPD approach assumes that events are generated through a two-step process. First, the type of event is selected according to some (unknown) mixture proportions. Next, the times of occurrence of the events are sampled from a corresponding survival distribution. Both of these steps can be modelled based on covariates. Performance was evaluated through a simulation study, considering sample size and levels of censoring. Additionally, an oncology-related case study was conducted to assess the ability to produce realistic results, and to demonstrate its implementation using both frequentist and Bayesian frameworks in R. Results: The simulation study showed good performance of the ESPD approach, with accuracy decreasing as sample sizes decreased and censoring levels increased. The average relative absolute error of the event probability (95%-confidence interval) ranged from 0.04 (0.00; 0.10) to 0.23 (0.01; 0.66) for 60% censoring and sample size 50, showing that increased censoring and decreased sample size resulted in lower accuracy. The approach yielded realistic results in the case study. Discussion: The ESPD approach can be used to model competing events in DES based on censored data. Further research is warranted to compare the approach to other modelling approaches for DES, and to evaluate its usefulness in estimating cumulative event incidences in a broader context.
Author IJzerman, Maarten J.
Franchini, Fanny
Fedyashov, Victor
Degeling, Koen
AuthorAffiliation 3 ARC Training Centre in Cognitive Computing for Medical Technologies , The University of Melbourne , Parkville , VIC , Australia
1 Cancer Health Services Research , Centre for Health Policy , Melbourne School of Population and Global Health , Faculty of Medicine , Dentistry and Health Sciences , The University of Melbourne , Melbourne , VIC , Australia
5 Erasmus School of Health Policy & Management , Erasmus University , Rotterdam , Netherlands
4 Department of Cancer Research , Peter MacCallum Cancer Centre , Melbourne , Australia
2 Cancer Health Services Research , Centre for Cancer Research , Faculty of Medicine , Dentistry and Health Sciences , The University of Melbourne , Melbourne , VIC , Australia
AuthorAffiliation_xml – name: 2 Cancer Health Services Research , Centre for Cancer Research , Faculty of Medicine , Dentistry and Health Sciences , The University of Melbourne , Melbourne , VIC , Australia
– name: 4 Department of Cancer Research , Peter MacCallum Cancer Centre , Melbourne , Australia
– name: 1 Cancer Health Services Research , Centre for Health Policy , Melbourne School of Population and Global Health , Faculty of Medicine , Dentistry and Health Sciences , The University of Melbourne , Melbourne , VIC , Australia
– name: 3 ARC Training Centre in Cognitive Computing for Medical Technologies , The University of Melbourne , Parkville , VIC , Australia
– name: 5 Erasmus School of Health Policy & Management , Erasmus University , Rotterdam , Netherlands
Author_xml – sequence: 1
  givenname: Fanny
  surname: Franchini
  fullname: Franchini, Fanny
– sequence: 2
  givenname: Victor
  surname: Fedyashov
  fullname: Fedyashov, Victor
– sequence: 3
  givenname: Maarten J.
  surname: IJzerman
  fullname: IJzerman, Maarten J.
– sequence: 4
  givenname: Koen
  surname: Degeling
  fullname: Degeling, Koen
BookMark eNp9kUuPFCEUhStmTBzH-QOuaummWl4FhRtjJj46mcSNrgkFl27GKiiB6sR_L_0wmZmFbLi5nPMB97xurkIM0DRvMdpQOsj3btnrtCGI0A0mfY8IftFcY85pJwdMrh7Vr5rbnB9QXVRKytl1c9jOywQzhOLDrjVxXuBUJZ9_5daH1vpsEhRo4VBFbfbzOuniY_jQlv2l2-UFjHfetEuKox795IuH3Opgj_6S_LgeLbWzVIU2-zfNS6enDLeX_ab5-eXzj7tv3f33r9u7T_edYYyXzlqhhcZjLwk3oidcCGb6EYxDWHPEMCXSYsa06THtncNI9nYADU5IYamjN832zLVRP6gl-VmnPypqr06NmHZKp-LNBMoiDqMxmNZLmZBk4AKDFbSyEBHcVtbHM2tZxxmsqR9PenoCfXoS_F7t4kFhxFklyEp4dyGk-HuFXNRcpwvTpAPENSsySEQ5YRxX6XCWmhRzTuCU8eU094r2U2WqY_bqlL06Zq8u2VcreWb998T_mP4CZsa5jA
CitedBy_id crossref_primary_10_1016_j_jval_2024_06_006
Cites_doi 10.1007/978-1-4612-4348-9
10.1007/s40273-014-0183-5
10.1177/0272989X12455462
10.1002/sim.4384
10.1057/jos.2009.25
10.1007/s00180-010-0217-1
10.1093/aje/kwp107
10.1002/sim.7501
10.3310/hta8110
10.1002/9780470870709
10.1016/j.jval.2021.07.016
10.1080/01621459.1999.10474144
10.1177/0272989X12455463
10.1177/0272989X18814770
10.3390/ijerph182212262
10.1016/j.jval.2012.04.014
10.1136/bmj-2022-071349
10.1214/aoms/1177729694
10.1016/j.jval.2020.01.016
ContentType Journal Article
Copyright Copyright © 2023 Franchini, Fedyashov, IJzerman and Degeling.
Copyright © 2023 Franchini, Fedyashov, IJzerman and Degeling. 2023 Franchini, Fedyashov, IJzerman and Degeling
Copyright_xml – notice: Copyright © 2023 Franchini, Fedyashov, IJzerman and Degeling.
– notice: Copyright © 2023 Franchini, Fedyashov, IJzerman and Degeling. 2023 Franchini, Fedyashov, IJzerman and Degeling
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fphar.2023.1255021
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Franchini et al
EISSN 1663-9812
ExternalDocumentID oai_doaj_org_article_d06ebcc13dd747928671ed73ef70276d
PMC10642769
10_3389_fphar_2023_1255021
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c446t-dd7a7a1b5926c7526774c5becf01a6041329d144ac5135ff1095d8eaef797d3f3
IEDL.DBID DOA
ISSN 1663-9812
IngestDate Wed Aug 27 01:26:47 EDT 2025
Thu Aug 21 18:36:23 EDT 2025
Fri Sep 05 13:40:24 EDT 2025
Tue Jul 01 02:53:17 EDT 2025
Thu Apr 24 23:08:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c446t-dd7a7a1b5926c7526774c5becf01a6041329d144ac5135ff1095d8eaef797d3f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Blythe Adamson, Flatiron Health, United States
Jim Nutaro, Oak Ridge National Laboratory (DOE), United States
Reviewed by: Faiz Ahmed Mohamed Elfaki, Qatar University, Qatar
These authors have contributed equally to this work and share first authorship
OpenAccessLink https://doaj.org/article/d06ebcc13dd747928671ed73ef70276d
PQID 2890362461
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_d06ebcc13dd747928671ed73ef70276d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10642769
proquest_miscellaneous_2890362461
crossref_citationtrail_10_3389_fphar_2023_1255021
crossref_primary_10_3389_fphar_2023_1255021
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-10-30
PublicationDateYYYYMMDD 2023-10-30
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-30
  day: 30
PublicationDecade 2020
PublicationTitle Frontiers in pharmacology
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Ripley (B21) 2022
Degeling (B9) 2022; 25
Češnovar (B6) 2022
Degeling (B10) 2019; 39
Lau (B18) 2009; 170
Siebert (B22) 2012; 15
Austin (B2) 2017; 36
Kullback (B17) 1951; 22
Marshall (B19) 2020; 23
Günal (B12) 2017; 4
Henningsen (B13) 2010; 26
Hinkley (B14) 1997
Koller (B16) 2012; 31
Karnon (B15) 2012; 32
Pintilie (B20) 2006
Coemans (B7) 2022; 378
Cover (B8) 1999
Barton (B3) 2004; 8
Team (B23) 2023
Andersen (B1) 1993
Caro (B5) 2014; 32
Fine (B11) 1999; 94
Vazquez-Serrano (B24) 2021; 18
Briggs (B4) 2012; 15
References_xml – volume-title: Bootstrap methods and their applications
  year: 1997
  ident: B14
– volume-title: RStan: the R interface to Stan
  year: 2023
  ident: B23
– volume-title: Statistical models based on counting processes
  year: 1993
  ident: B1
  doi: 10.1007/978-1-4612-4348-9
– volume-title: Boot: bootstrap R (S-plus) functions
  year: 2022
  ident: B21
– volume: 32
  start-page: 943
  year: 2014
  ident: B5
  article-title: Decision-analytic models: current methodological challenges
  publication-title: Pharmacoeconomics
  doi: 10.1007/s40273-014-0183-5
– volume-title: Elements of information theory
  year: 1999
  ident: B8
– volume: 32
  start-page: 701
  year: 2012
  ident: B15
  article-title: Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force–4
  publication-title: Med. Decis. Mak.
  doi: 10.1177/0272989X12455462
– volume: 31
  start-page: 1089
  year: 2012
  ident: B16
  article-title: Competing risks and the clinical community: irrelevance or ignorance?
  publication-title: Stat. Med.
  doi: 10.1002/sim.4384
– volume: 4
  start-page: 42
  year: 2017
  ident: B12
  article-title: Discrete event simulation for performance modelling in health care: a review of the literature
  publication-title: J. Simul.
  doi: 10.1057/jos.2009.25
– volume-title: Cmdstanr: R interface to 'CmdStan
  year: 2022
  ident: B6
– volume: 26
  start-page: 443
  year: 2010
  ident: B13
  article-title: maxLik: a package for maximum likelihood estimation in R
  publication-title: Comput. Stat.
  doi: 10.1007/s00180-010-0217-1
– volume: 170
  start-page: 244
  year: 2009
  ident: B18
  article-title: Competing risk regression models for epidemiologic data
  publication-title: Am. J. Epidemiol.
  doi: 10.1093/aje/kwp107
– volume: 36
  start-page: 4391
  year: 2017
  ident: B2
  article-title: Practical recommendations for reporting Fine-Gray model analyses for competing risk data
  publication-title: Stat. Med.
  doi: 10.1002/sim.7501
– volume: 8
  start-page: 1
  year: 2004
  ident: B3
  article-title: The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
  publication-title: Health Technol. Assess. Winch. Engl.
  doi: 10.3310/hta8110
– volume-title: Competing risks: a practical perspective
  year: 2006
  ident: B20
  doi: 10.1002/9780470870709
– volume: 25
  start-page: 104
  year: 2022
  ident: B9
  article-title: Comparing modeling approaches for discrete event simulations with competing risks based on censored individual patient data: a simulation study and illustration in colorectal cancer
  publication-title: Value Health
  doi: 10.1016/j.jval.2021.07.016
– volume: 94
  start-page: 496
  year: 1999
  ident: B11
  article-title: A proportional hazards model for the subdistribution of a competing risk
  publication-title: J. Am. Stat. Assoc.
  doi: 10.1080/01621459.1999.10474144
– volume: 15
  start-page: 690
  year: 2012
  ident: B22
  article-title: State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3
  publication-title: Value Health
  doi: 10.1177/0272989X12455463
– volume: 39
  start-page: 57
  year: 2019
  ident: B10
  article-title: Comparing strategies for modeling competing risks in discrete-event simulations: a simulation study and illustration in colorectal cancer
  publication-title: Med. Decis. Mak.
  doi: 10.1177/0272989X18814770
– volume: 18
  start-page: 12262
  year: 2021
  ident: B24
  article-title: Discrete-event simulation modeling in healthcare: a comprehensive review
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph182212262
– volume: 15
  start-page: 835
  year: 2012
  ident: B4
  article-title: Model parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling good research practices task force-6
  publication-title: Value Health
  doi: 10.1016/j.jval.2012.04.014
– volume: 378
  start-page: e071349
  year: 2022
  ident: B7
  article-title: Bias by censoring for competing events in survival analysis
  publication-title: BMJ
  doi: 10.1136/bmj-2022-071349
– volume: 22
  start-page: 79
  year: 1951
  ident: B17
  article-title: On information and sufficiency
  publication-title: Ann. Math. Statistics
  doi: 10.1214/aoms/1177729694
– volume: 23
  start-page: 566
  year: 2020
  ident: B19
  article-title: Addressing challenges of economic evaluation in precision medicine using dynamic simulation modeling
  publication-title: Value Health
  doi: 10.1016/j.jval.2020.01.016
SSID ssj0000399364
Score 2.3458884
Snippet Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific...
Background: Although several strategies for modelling competing events in discrete event simulation (DES) exist, a methodological gap for the event-specific...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1255021
SubjectTerms bayesian framework
censored data
competing risks modelling
discrete event simulation
frequentist implementation
Pharmacology
SummonAdditionalLinks – databaseName: Scholars Portal: Open Access Journals [open access]
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS9xAFB5EL71IaytubcsUyl40Nsn8SFIQaUtlKVQ8uOBtmMwPXVizullL97_ve5PZ1YD21FuYzJBMXibv-zLvfY-QT9Z65l1pklJ6nnAJBKVG2UrBhLO-FNrV-L_j15kcjfnPS3G5QVbljuIDbJ-kdlhPajyfHv25W57Agj9Gxgn-9rO_vdYo7ZmzI3DXIsW88q2wX4ShfBHuhy8zemPJu9yZZ4b2_FOQ8e9hz37k5CNXdPqSbEcMSb92Rn9FNlyzQ4bnnQj18pBePORUtYd0SM8f5KmXr8nvIAgcooSaK2oCbsYjDDJv6aShmKg7ByxNg7gTbSc3scTXFwposWtNMEMTo4woVqTptL6Bc1PdWBy_LqMFLVG0_A0Zn_64-D5KYvWFxABFXCTWFrrQWS2qXJpC5BKAohFgcp9mWqYcK9RboGPaiIwJ7zMAa7Z02vmiKizzbJdsNrPG7RHKUidKwAY1l5pXngMG0TbNtZc81blzA5KtnrkyUZocK2RMFVAUtJMKdlJoJxXtNCAH6zG3nTDHP3t_Q1Oue6KodmiYza9UXKPKptLVxmQMps6LKkfpP2cLBjMC8i7tgHxcvQgKFiHurOjGze5bhbu1gAS4hAuVvTekd8X-mWZyHeS8M-SAhaze_o973CcvcN7Bu6bvyOZifu_eA2xa1B_CWvgLFoUcKw
  priority: 102
  providerName: Scholars Portal
Title Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
URI https://www.proquest.com/docview/2890362461
https://pubmed.ncbi.nlm.nih.gov/PMC10642769
https://doaj.org/article/d06ebcc13dd747928671ed73ef70276d
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iyYv4xPVFBPGi1bR5tPWmoiyC4kHBW0jz0AXtirsK_ntn0u66vejFSylpStvMpPN97eQbQvadCzz4wiaFCiIRCghKhbKVkkvvQiGNr_B7x82t6j-I60f5OFPqC3PCGnngZuBOHFO-sjblzgHyLTPUY_Mu5z7kwKiUw7cvK9kMmYrvYIy7SjSrZICFlSfh7dmg_mfGjyGmS5alnUgUBfs7KLObIzkTdK6WyGKLFulZc5fLZM7XK-TgrpGb_jqi9z-rp0ZH9IDe_QhRf62Szyj9G_OB6idqI0LGPUwnH9FBTXFJ7jugZhplnOho8NoW8zqlgAub1gTXYmI-EcXaM42qN7BramqH508LZkFLK0--Rh6uLu8v-klbZyGxQAbHCYysyU1ayTJTNpeZAkhoJRg3sNQoJrAWvQPiZaxMuQwhBVjmCm_ABGXueODrZL4e1n6DUM68LAAFVEIZUQYBaMM4lpmgBDOZ9z2STsZc21aEHGthvGggI2gnHe2k0U66tVOPHE7PeWskOH7tfY6mnPZE-ezYAE6lW6fSfzlVj-xNHEHDdMN_KKb2w4-Rxv-yEPOFggsVHQ_pXLF7pB48R-HuFNlersrN_7jHLbKAzx3jKNsm8-P3D78DAGlc7ca5ANsbUXwDtEwUoQ
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implementing+competing+risks+in+discrete+event+simulation%3A+the+event-specific+probabilities+and+distributions+approach&rft.jtitle=Frontiers+in+pharmacology&rft.au=Fanny+Franchini&rft.au=Fanny+Franchini&rft.au=Victor+Fedyashov&rft.au=Maarten+J.+IJzerman&rft.date=2023-10-30&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-9812&rft.volume=14&rft_id=info:doi/10.3389%2Ffphar.2023.1255021&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d06ebcc13dd747928671ed73ef70276d
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon